<DOC>
	<DOCNO>NCT00002522</DOCNO>
	<brief_summary>RATIONALE : Drugs use chemotherapy use different way stop tumor cell divide stop grow die . Combining chemotherapy bone marrow peripheral stem cell transplantation may allow doctor give high dos chemotherapy drug kill tumor cell . PURPOSE : Phase II trial study effectiveness combination chemotherapy follow bone marrow peripheral stem cell transplantation treat patient relapsed refractory Hodgkin 's lymphoma .</brief_summary>
	<brief_title>Combination Chemotherapy Followed Bone Marrow Peripheral Stem Cell Transplantation Treating Patients With Relapsed Refractory Hodgkin 's Lymphoma</brief_title>
	<detailed_description>OBJECTIVES : - Determine curative potential high-dose cyclophosphamide , etoposide , cisplatin ( CEP ) follow syngeneic autologous bone marrow and/or autologous peripheral blood stem cell ( PBSC ) rescue patient relapse refractory stage I-IV Hodgkin 's lymphoma . - Determine overall response rate survival patient treat regimen . - Determine toxicity regimen patient . - Determine difference rate engraftment , response , survival patient treat bone marrow v PBSC transplantation . - Determine response rate survival patient treat late consolidative radiotherapy recovery transplantation . - Determine toxicity late consolidative radiotherapy recovery transplantation patient . OUTLINE : Syngeneic autologous bone marrow and/or autologous peripheral blood stem cell ( PBSC ) harvest . Syngeneic bone marrow transplantation prefer patient qualify identical twin donor . Patients without syngeneic donor history lymphomatous involvement bone marrow profoundly hypocellular undergo harvest PBSC alone . Patients without syngeneic donor history lymphomatous involvement bone marrow undergo harvest autologous bone marrow PBSC . Patients receive condition comprise cyclophosphamide IV 1 hour day -6 -3 etoposide IV 1 hour every 12 hour cisplatin IV continuously day -6 -4 . Bone marrow and/or PBSC infuse day 0 . ( Patients require 25 bag stem cell receive bone marrow transplantation day 0 PBSC transplantation day 1 . ) After recovery transplantation , eligible patient receive consolidative radiotherapy site prior bulk disease ( great 5 cm ) present time transplantation site disease present time transplantation . Patients follow 3 , 6 , 12 month annually thereafter . PROJECTED ACCRUAL : A maximum 30 patient accrue study .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Etoposide phosphate</mesh_term>
	<mesh_term>Cisplatin</mesh_term>
	<mesh_term>Cyclophosphamide</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<criteria>DISEASE CHARACTERISTICS : Histologically proven stage IIV Hodgkin 's lymphoma Must refractory relapse disease , define 1 following : Failure achieve complete remission ( CR ) 4 course conventionaldose frontline chemotherapy Disease second great remission Patients encourage undergo transplantation prior third salvage regimen Patients previously treat multiple regimen consider casebycase basis No chemoresistant disease , define active progression tumor growth great 25 % volume firstline chemotherapy Patients respond secondline chemotherapy may eligible Stable residual mass conventionaldose chemotherapy consider treatment failure Active ( refractory relapse ) disease must prove histologically documented gallium nitrate uptake Syngeneic marrow transplantation offer patient consent identical twin donor No CNS involvement lymphoma PATIENT CHARACTERISTICS : Age : 15 60 ( select patient age 70 may eligible ) Performance status : ECOG 02 Life expectancy : Not specify Hematopoietic : WBC great 4,000/mm^3 Absolute neutrophil count great 2,000/mm^3 Platelet count great 100,000/mm^3 Hepatic : Bilirubin le 2.0 mg/dL SGOT SGPT less 2 time upper limit normal Albumin great 3.0 g/dL Renal : Must meet 1 follow criterion : Creatinine le 1.8 mg/dL Creatinine clearance great 60 mL/min BUN le 20 mg/dL Cardiovascular : Left ventricular ejection fraction least 50 % Pulmonary : DLCO , FEV_1 , FVC great 50 % predict OR Resting pO_2 great 70 mm Hg room air Other : HIV negative No severe neurologic emotional disorder No active infection No disease would limit life expectancy Not pregnant Fertile patient must use effective contraception Adequate psychosocial support require PRIOR CONCURRENT THERAPY : Biologic therapy Not specify Chemotherapy See Disease Characteristics Endocrine therapy Not specify Radiotherapy Not specify Surgery Not specify</criteria>
	<gender>All</gender>
	<minimum_age>15 Years</minimum_age>
	<maximum_age>70 Years</maximum_age>
	<verification_date>September 2010</verification_date>
	<keyword>stage I adult Hodgkin lymphoma</keyword>
	<keyword>stage II adult Hodgkin lymphoma</keyword>
	<keyword>stage III adult Hodgkin lymphoma</keyword>
	<keyword>stage IV adult Hodgkin lymphoma</keyword>
	<keyword>recurrent adult Hodgkin lymphoma</keyword>
</DOC>